NCT03913117View on ClinicalTrials.gov

Study of Treatment for HPV16+ ASC-US or LSIL

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 10, 2023

Primary Completion Date

May 31, 2027

Study Completion Date

September 30, 2027

Conditions
ASC-USLSIL
Interventions
BIOLOGICAL

pNGVL4aCRTE6E7L2

Naked pNGVL4aCRTE6E7L2 DNA plasmid

BIOLOGICAL

TA-CIN

TA-CIN is a single fusion protein comprised of HPV16 L2, E7 and E6 proteins linked in tandem.

Trial Locations (2)

21231

RECRUITING

Johns Hopkins University, Baltimore

Alabama

RECRUITING

"UAB , The University of Alabama at Birmingham"

All Listed Sponsors
collaborator

Johns Hopkins University

OTHER

lead

University of Alabama at Birmingham

OTHER